NK cell and PARP medicine for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether giving special immune cells (NK cells) along with a PARP inhibitor can help people with acute myeloid leukemia (AML). It focuses on people whose AML is coming back or not fully responding, and who have certain lab signs that help show the disease is still active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed AML (a specific leukemia type), but not acute promyelocytic leukemia
- You may qualify if your AML is relapsed or not responding, and your bone marrow and blood blast counts are under 20%
- You have rising minimal residual disease (MRD) while still in blood remission (more than 3-fold increase)
- You received AML treatment before, such as intensive chemotherapy, certain medicines (azacitidine/decitabine/cytarabine/venetoclax/FLT3 inhibitors), or a stem cell transplant
- You must wait long enough after your last AML treatment before starting this study (about 107 days for chemotherapy, longer rules for other drugs)
- You need an available donor for the NK cell transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a combination of specially prepared immune cells (CIML NK cells) and a drug called venetoclax for people with acute myeloid leukemia (AML) or a related condition. The goal is to see if this treatment can help control the leukemia and possibly prepare for a stem cell transplant.
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.